Purabond

DEVICE4 trials

Sponsors

IRCCS San Raffaele, University of Liverpool, St. James's Hospital, Ireland, The Royal Wolverhampton Hospitals NHS Trust

Conditions

Head and Neck CancerHemorrhageHemostaticHemostaticsKidney CancerOral CavityOropharynxPain

Unknown Phase

Clinical Study of Patients Treated With PuraBond Haemostatic Agent During Abdominal Aorta Open Repair

RecruitingNCT05733585

IRCCS San RaffaeleHemostatic

Start: 2023-02-15End: 2027-10-31Target: 100Updated: 2026-03-27

PuraBond® and Pain Following Resection of Oral or Oropharyngeal Mucosal Lesions

CompletedNCT05773781

University of LiverpoolHemorrhage, Hemostatics, Oral Cavity +2

Start: 2023-10-16End: 2024-08-30Updated: 2025-09-16

RADA16 for Reducing Drain Output Trajectory Following Neck Dissection

Not yet recruitingNCT06178237

St. James's Hospital, IrelandHead and Neck Cancer

Start: 2024-03-31End: 2026-06-30Target: 208Updated: 2023-12-20

A Novel Haemostatic Agent for Robotic Partial Nephrectomy

WithdrawnNCT07284953

The Royal Wolverhampton Hospitals NHS TrustKidney Cancer, Renal Cell Carcinoma

Start: 2026-03-01End: 2027-03-01Updated: 2026-03-13

Related Papers

The effect of PuraBond® on postoperative pain following transoral resections of primary oral or oropharyngeal neoplastic mucosal lesions: A blinded randomised controlled study (PuraBond® PROOF)

European Journal of Surgical Oncology2025-07-15